What are the definitions and indications for pleurodesis, Video-Assisted Thoracic Surgery (VATS), and thoracotomy in managing pleural effusions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Definitions and Indications for Pleurodesis, VATS, and Thoracotomy in Pleural Effusions

For symptomatic malignant pleural effusions, pleurodesis is the primary definitive treatment option for patients with good performance status and expandable lungs, while VATS is indicated for both diagnosis and treatment of undiagnosed effusions, and thoracotomy should be reserved only for cases where VATS fails or extensive surgical repair is needed. 1

Definitions and Technical Aspects

Pleurodesis

  • A procedure that creates adhesions between visceral and parietal pleura to prevent fluid reaccumulation 2
  • Can be performed via two main methods:
    • Chemical pleurodesis: Installation of sclerosing agents through a chest tube (talc slurry)
    • Talc poudrage: Insufflation of talc powder during thoracoscopy 2

Video-Assisted Thoracic Surgery (VATS)

  • Minimally invasive thoracoscopic procedure performed under general anesthesia
  • Allows direct visualization of the pleural space through small incisions
  • Enables both diagnostic (pleural biopsies) and therapeutic interventions (talc poudrage) 3

Thoracotomy

  • Traditional open surgical approach with larger incision and greater tissue disruption
  • Associated with higher perioperative mortality (12%) and significant morbidity 1

Indications

Pleurodesis

  • Primary indication: Symptomatic malignant pleural effusion in patients with good performance status 1
  • Specifically indicated when:
    • Lung is fully expandable after fluid drainage
    • Patient has recurrent symptomatic effusion after initial thoracentesis 2
    • Patient has reasonable life expectancy (>1 month)
  • Contraindications:
    • Trapped lung (inability to fully expand)
    • Poor performance status 1
    • Concomitant use of corticosteroids may reduce effectiveness 1

VATS

  • Indicated for:
    • Undiagnosed pleural effusions requiring tissue diagnosis 1
    • Combined diagnostic and therapeutic management in one procedure
    • Talc poudrage for malignant pleural effusions (90% success rate) 1
    • Management of pleuro-peritoneal leaks in peritoneal dialysis patients (88% success rate) 1
  • Benefits over thoracotomy:
    • Reduced operating time (33 vs 44 minutes) 4
    • Shorter drainage time (3 vs 5 days) 4
    • Fewer complications (2% vs 7%) 4
    • Shorter hospital stay (5 vs 7 days) 4
    • Higher therapeutic success rate (81% vs 65%) 4

Thoracotomy

  • Reserved for:
    • Cases where VATS fails
    • Need for extensive surgical repair of diaphragmatic defects 1
    • Parietal pleurectomy for recurrent effusions when other methods fail
    • Decortication for trapped lung 1

Efficacy and Outcomes

Pleurodesis Success Rates

  • Talc pleurodesis: 86.8% success rate at 90 days 5
  • Tetracycline: 73.8% success rate 5
  • Bleomycin: 64.3% success rate 5

VATS Outcomes

  • Diagnostic yield: Specific histologic diagnosis in all patients 3
  • Therapeutic success: 92.7% control of effusion recurrence in long-term follow-up 3
  • Complications: 3.1% rate 3
  • Mortality: 0.81% 3

Management Algorithm for Pleural Effusions

  1. If diagnosis is known and lung is expandable:

    • Small bore (10-14F) intercostal tube drainage with chemical pleurodesis 1
    • Talc is the preferred agent over other sclerosants (tetracycline, bleomycin) 2, 5
  2. If diagnosis is uncertain:

    • VATS for both diagnosis and treatment 1
    • Allows for pleural biopsies and talc poudrage in one procedure
  3. For malignant effusions with chemotherapy-responsive tumor:

    • Consider systemic therapy with or without pleurodesis 1
  4. For trapped lung:

    • Consider pleuroperitoneal shunt or VATS with decortication 1
    • Indwelling pleural catheter may be appropriate
  5. When VATS fails or is contraindicated:

    • Consider thoracotomy for extensive surgical repair or pleurectomy 1

Important Considerations and Pitfalls

  • Talc poudrage and talc slurry are both effective methods for pleurodesis, with no clear superiority of one over the other for critical outcomes 2
  • Large-particle (graded) talc is recommended over mixed-particle size to reduce the risk of acute respiratory distress syndrome 2
  • Re-expansion pulmonary edema is a risk if more than 1.5L of fluid is removed at once 1
  • Indwelling pleural catheters are an alternative to pleurodesis, with infection occurring in 8-10% of cases 1
  • The choice between talc poudrage and slurry should depend on local expertise, need for tissue diagnosis, and patient-specific factors 2

Pleurodesis, VATS, and thoracotomy represent a spectrum of interventions for managing pleural effusions, with increasing invasiveness but also increasing capabilities for complex cases. The choice of procedure should be guided by the diagnostic certainty, lung expandability, and patient's overall clinical status.

References

Guideline

Management of Pleural Effusions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.